Search

CA-3070246-C - TYROTHRICIN FOR USE IN THE TREATMENT OR PROPHYLAXIS OF BODY ODOUR AND PREPARATIONS THEREFOR

CA3070246CCA 3070246 CCA3070246 CCA 3070246CCA-3070246-C

Abstract

The invention relates to the therapeutic or non-therapeutic use of tyrothricin for the treatment and/or prophylaxis of body odour in humans, preferably by local (topical) surface application and/or preferably by application to wound-free skin and/or mucosa. A therapeutic, preferably pharmaceutical, or non-therapeutic, preferably cosmetic, composition is described for the treatment and/or prophylaxis of body odour in humans, the composition containing tyrothricin and a keratolytic. A kit, containing tyrothricin and a keratolytic, and a footwear article, which contains tyrothricin, are also described.

Inventors

  • Thomas Leibbrand

Assignees

  • Thomas Leibbrand

Dates

Publication Date
20260505
Application Date
20180703
Priority Date
20170720

Claims (20)

  1. CA 3070246- 22 - CLAIMS: 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9. A use of tyrothricin for treatment or prophylaxis of human body odor, wherein the body odor emanates from the foot. Tyrothricin for use in the treatment or prophylaxis of human body odor, wherein the body odor emanates from the foot. The use as claimed in claim 1 or 2, wherein the body odor is associated with bacterial colonization, bacterial metabolism products, perspiration, or a combination thereof. The use as claimed in any one of claims 1 to 3, wherein the tyrothricin is formulated for topical application. A composition comprising tyrothricin and at least one keratolytic, for use in the treatment or prophylaxis of human body odor. The composition for use of claim 5, wherein the composition is a pharmaceutical composition. The composition for use as claimed in claim 5 or 6, wherein the keratolytic is selected from the group consisting of α-hydroxy acids; acitretin; adapalene; aluminum oxide; azelaic acid; benzoyl peroxide; urea; isotretinoin; monochloroacetic acid; motretinide; retinoids; salicylic acid; shale oils; selenium disulfide; tazarotene; tars; tretinoin; and mixtures thereof. The composition for use as claimed in any one of claims 5 to 7, in which the keratolytic is urea. The composition for use as claimed in claim 8, in which urea is present in an amount within a range from 0.5% to 20.0% by weight, based on the total mass of the composition. CA 3070246- 23 -
  10. 10. The composition for use as claimed in claim 8, in which urea is present in an amount within a range from 1.0% to 15.0% by weight, based on the total mass of the composition.
  11. 11. The composition for use as claimed in claim 8, in which urea is present in an amount within a range from 3.0% to 12.0% by weight, based on the total mass of the composition.
  12. 12. The composition for use as claimed in any one of claims 5 to 11, in which tyrothricin is present in an amount within a range from 0.01% to 0.5% by weight, based on the total mass of the composition.
  13. 13. The composition for use as claimed in any one of claims 5 to 11, in which tyrothricin is present in an amount within a range from 0.05% to 0.2%by weight, based on the total mass of the composition.
  14. 14. The composition for use as claimed in any one of claims 5 to 13, further comprising one or more polyethylene glycols.
  15. 15. The composition for use as claimed in any one of claims 5 to 13, further comprising propylene glycol.
  16. 16. The composition for use as claimed in any one of claims 5 to 15, formulated for topical administration in a form selected from the group consisting of cream, gel, lotion, powder, powder spray, oil, roll-on formulation, ointment, foam, spray, stick, and tincture.
  17. 17. The composition for use as claimed in any one of claims 5 to 15, formulated for topical administration in a form selected from the group consisting of cream, gel, lotion, powder, oil, roll-on formulation and ointment.
  18. 18. A pharmaceutical composition comprising CA 3070246- 24 - tyrothricin in an amount within a range from 0.01% to 0.5% by weight, based on the total mass of the composition, urea in an amount within a range from 0.5% to 20.0% by weight, based on the total mass of the composition, and polyethylene glycols and/or propylene glycol in the range from 40% to 90% by weight, based on the total mass of the composition,
  19. 19. The composition as claimed in claim 18, formulated for topical administration in a form selected from the group consisting of cream, gel, lotion, powder, powder spray, oil, roll on formulation, ointment, foam, spray, stick, and tincture.
  20. 20. A kit comprising the following spatially separated constituents: a) a composition formulated for topical administration and comprising tyrothricin in a diluent or carrier, and b) at least one composition suitable for topical administration and comprising at least one keratolytic in a diluent or carrier, wherein the keratolytic comprises urea.

Description

TYROTHRICIN FOR USE IN THE TREATMENT OR PROPHYLAXIS OF BODY ODOUR AND PREPARATIONS THEREFOR The present invention relates to the therapeutic or nontherapeutic use of tyrothricin for treatment and/or prophylaxis of human body odor, preferably by local (topical), superficial application and/or preferably by applicatio~ to the wound-free skin and/or mucosa. The invention further relates to a therapeutic, preferably 5 pharmaceutical, or nontherapeutic, preferably cosmetic, composition, comprising tyrothricin and a keratolytic, for treatment and/or prophylaxis of human body odor. The invention likewise relates to a kit comprising tyrothricin and a keratolytic, and also to a footwear article comprising tyrothricin. Body odor, especially in the form of unpleasant-smelling human body odor, may emanate in particular from the surface of the skin, especially from the foot or the armpit or from poorly ventilated skin folds 10 ("intertriginous regions"), for instance in the groin area (inguinal) or under the breast area (submammary), or else may emanate from mucosa, for instance the oral mucosa or the vaginal mucosa. Body odor of the aforementioned type or origin that is perceived as unpleasant, according to current knowledge, is generally caused and/or promoted and/or triggered by bacterial colonization and/or certain bacterial metabolism products. 15 In the case of origination from the surface of the skin, body odor perceived as unpleasant is favored or promoted particularly by perspiration, especially by increased or excessive perspiration. It is apparently the case that metabolism products of some microorganisms that colonize the surface of the skin, particularly bacteria that break down skin constituents and other substances released with perspiration, play an important role in the formation of this body odor. It also seems that the exact composition and amount of 20 the bacterial colonization of parts of the skin can ·influence the type and extent of odor evolution. By contrast, only minor odor, if any, emanates from freshly formed, undecomposed perspiration. Unwanted odor formation at the surface of the skin is favored or promoted by influencing factors such as severe to excessive perspiration and poorly ventilated clothing. Excessive sweating is also known by the term "hyperhidrosis", especially by the term "primary focal hyperhidrosis". Excessive perspiration in the foot 25 region is also known by the terms "Hyperhidrosis plantaris" and "Hyperhydrosis pedislpedum". Excessive sweating in the armpit region is also known by the term "Hyperhidrosis axillaris". Excessive perspiration is often associated with a phenomenon known as "bromhidrosis": bromhidrosis refers to malodorous perspiration and is a specific type of hyperhidrosis where the perspiration produced to an enhanced degree constantly soaks the horny layer of the skin and promotes the propagation of the germ flora present therein. The degradation of the keratin in the horny layer gives rise to degradation 5 products, for example short-chain fatty acids and amines, which can be further metabolized by particular germs in said germ flora to give various secondary products. Some of these germs seem to have a multitude of metabolic pathways, some of which are unusual with regard to the occurrence of particular metabolic products: one peculiarity is, for example, the synthesis of mycothiol rather than glutathione which is observed in the case of some microorganisms. Moreover, volatile (in particular short-chain) organic thiols 10 also seem to form as metabolic products of some of the germs in said germ flora. Volatile organic thiols often have an odor perceived by humans as being particularly unpleasant, in some cases as disgusting, and can therefore make a considerable contribution to a body odor perceived to be unpleasant- particularly in the region of the groin region, the armpits and the feet, for instance the spaces between the toes. Apocrine sweat or sebum that originates from the apocrine glands is degraded by bacteria, which leads to 15 significant odor that can vary according to the composition of the degradation or metabolism products. "Apocrine secretion" is generally understood to mean the process when secretory vesicles with surrounding apical cytoplasm are pinched off from the gland cell by part of the cell membrane. The phenomenon of bromhidrosis can be even further differentiated into the sub-categories of "apocrine bromhidrosis" and "eccrine bromhidrosis". Eccrine glands are glands that release their secretion to a clear 20 surface (for example the skin or the digestive tract), with formation of secretion without loss of cytoplasm identifiable by light microscopy on secretion (e.g. small perspiration glands). Apocrine bromhidrosis refers to marked secretion of perspiration, predominantly by apocrine axillary perspiration glands. Organic constituents of apocrine perspiration are then broken down by bacteria to give unpleasant-smelling metabolism